Evotec SE (EVO) Financials

EVO Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 1.9 billion 1.1 billion
Dec. 31, 2025 2.1 billion 1.1 billion
Sept. 30, 2025 2.1 billion 1.1 billion
June 30, 2025 2.5 billion 1.3 billion

EVO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -7.3 million ?
Dec. 31, 2025 54.7 million ?
Sept. 30, 2025 -103.0 million ?
June 30, 2025 3.2 million ?

EVO Net Income

No data available :(

EVO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 510.2 million 342.8 million -
Dec. 31, 2025 559.0 million 228.7 million 175.0 million
Sept. 30, 2025 278.4 million 455.0 million -
June 30, 2025 481.5 million 491.5 million -

EVO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 407.0 million
Dec. 31, 2025 208.3 million
Sept. 30, 2025 417.0 million
June 30, 2025 418.7 million

EVO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 4.8 million 11.7 million 51.0 million -
Dec. 31, 2025 17.0 million 11.4 million 51.6 million -
Sept. 30, 2025 23.7 million 10.2 million 49.7 million -
June 30, 2025 28.1 million 9.7 million 49.0 million -

EVO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 182.5 million 184.3 million
Dec. 31, 2025 294.5 million 203.3 million
Sept. 30, 2025 192.3 million 192.4 million
June 30, 2025 201.8 million 191.7 million

EVO

Price: $2.80

52 week price:
2.31
4.44

Payout Ratio Range:
-118.48%
-19.09%

Earnings Per Share: -0.64 USD

Exchange: NMS

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Country: Germany

Volume: 14985

Market Capitalization: 1.0 billion

Links: